STAT5 activation correlates with erythropoietin receptor mediated erythroid differentiation of an erythroleukemia cell line

Ken Iwatsuki, Takaho Endo, Hiroyuki Misawa, Masahiro Yokouchi, Akira Matsumoto, Motoaki Ohtsubo, Kazuhiro J. Mori, Akihiko Yoshimura

Research output: Contribution to journalArticle

77 Citations (Scopus)

Abstract

Interaction between erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. EPO has been shown to activate the JAK2-STAT5 pathway in various hematopoietic cell lines, although the physiological role of this pathway is unclear. We have previously shown that epidermal growth factor activates a chimeric receptor bearing the extracellular domain of the epidermal growth factor receptor linked to the cytoplasmic domain of the EPO receptor, resulting in proliferation of interleukin-3-dependent hematopoietic cells and erythroid differentiation (globin synthesis) of EPO-responsive erythroleukemia cells. In the present study, we introduced various deletion and tyrosine to phenylalanine substitution in the cytoplasmic domain of the chimeric receptor and expressed these mutant chimeras in an EPO-responsive erythroleukemia cell line, ELM-I-1. Mutant chimeric receptors retaining either Tyr343 or Tyr401 could activate STAT5, judged by tyrosine-phosphorylation of STAT5 and induction of CIS, a target gene of STAT5. These mutants were able to induce erythroid differentiation. However, a chimeric receptor containing both Y343F and Y401F mutations could not activate STAT5 nor induce erythroid differentiation. Thus, Tyr343 or Tyr401 of the EPO receptor are independently necessary for erythroid differentiation as well as STAT5 activation. Moreover, exogenous expression of dominant-negative STAT5 suppressed EPO-dependent erythroid differentiation. These findings suggest that STAT5.

Original languageEnglish
Pages (from-to)8149-8152
Number of pages4
JournalJournal of Biological Chemistry
Volume272
Issue number13
DOIs
Publication statusPublished - 1997 Mar 28
Externally publishedYes

Fingerprint

Erythropoietin Receptors
Leukemia, Erythroblastic, Acute
Erythropoietin
Chemical activation
Cells
Cell Line
Tyrosine
Bearings (structural)
Phosphorylation
Globins
Interleukin-3
Phenylalanine
Epidermal Growth Factor Receptor
Epidermal Growth Factor
Cell Differentiation
Substitution reactions
Genes
Membranes
Mutation

ASJC Scopus subject areas

  • Biochemistry

Cite this

STAT5 activation correlates with erythropoietin receptor mediated erythroid differentiation of an erythroleukemia cell line. / Iwatsuki, Ken; Endo, Takaho; Misawa, Hiroyuki; Yokouchi, Masahiro; Matsumoto, Akira; Ohtsubo, Motoaki; Mori, Kazuhiro J.; Yoshimura, Akihiko.

In: Journal of Biological Chemistry, Vol. 272, No. 13, 28.03.1997, p. 8149-8152.

Research output: Contribution to journalArticle

Iwatsuki, Ken ; Endo, Takaho ; Misawa, Hiroyuki ; Yokouchi, Masahiro ; Matsumoto, Akira ; Ohtsubo, Motoaki ; Mori, Kazuhiro J. ; Yoshimura, Akihiko. / STAT5 activation correlates with erythropoietin receptor mediated erythroid differentiation of an erythroleukemia cell line. In: Journal of Biological Chemistry. 1997 ; Vol. 272, No. 13. pp. 8149-8152.
@article{afb1c234e18c4636b00796ded14e7b70,
title = "STAT5 activation correlates with erythropoietin receptor mediated erythroid differentiation of an erythroleukemia cell line",
abstract = "Interaction between erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. EPO has been shown to activate the JAK2-STAT5 pathway in various hematopoietic cell lines, although the physiological role of this pathway is unclear. We have previously shown that epidermal growth factor activates a chimeric receptor bearing the extracellular domain of the epidermal growth factor receptor linked to the cytoplasmic domain of the EPO receptor, resulting in proliferation of interleukin-3-dependent hematopoietic cells and erythroid differentiation (globin synthesis) of EPO-responsive erythroleukemia cells. In the present study, we introduced various deletion and tyrosine to phenylalanine substitution in the cytoplasmic domain of the chimeric receptor and expressed these mutant chimeras in an EPO-responsive erythroleukemia cell line, ELM-I-1. Mutant chimeric receptors retaining either Tyr343 or Tyr401 could activate STAT5, judged by tyrosine-phosphorylation of STAT5 and induction of CIS, a target gene of STAT5. These mutants were able to induce erythroid differentiation. However, a chimeric receptor containing both Y343F and Y401F mutations could not activate STAT5 nor induce erythroid differentiation. Thus, Tyr343 or Tyr401 of the EPO receptor are independently necessary for erythroid differentiation as well as STAT5 activation. Moreover, exogenous expression of dominant-negative STAT5 suppressed EPO-dependent erythroid differentiation. These findings suggest that STAT5.",
author = "Ken Iwatsuki and Takaho Endo and Hiroyuki Misawa and Masahiro Yokouchi and Akira Matsumoto and Motoaki Ohtsubo and Mori, {Kazuhiro J.} and Akihiko Yoshimura",
year = "1997",
month = "3",
day = "28",
doi = "10.1074/jbc.272.13.8149",
language = "English",
volume = "272",
pages = "8149--8152",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "13",

}

TY - JOUR

T1 - STAT5 activation correlates with erythropoietin receptor mediated erythroid differentiation of an erythroleukemia cell line

AU - Iwatsuki, Ken

AU - Endo, Takaho

AU - Misawa, Hiroyuki

AU - Yokouchi, Masahiro

AU - Matsumoto, Akira

AU - Ohtsubo, Motoaki

AU - Mori, Kazuhiro J.

AU - Yoshimura, Akihiko

PY - 1997/3/28

Y1 - 1997/3/28

N2 - Interaction between erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. EPO has been shown to activate the JAK2-STAT5 pathway in various hematopoietic cell lines, although the physiological role of this pathway is unclear. We have previously shown that epidermal growth factor activates a chimeric receptor bearing the extracellular domain of the epidermal growth factor receptor linked to the cytoplasmic domain of the EPO receptor, resulting in proliferation of interleukin-3-dependent hematopoietic cells and erythroid differentiation (globin synthesis) of EPO-responsive erythroleukemia cells. In the present study, we introduced various deletion and tyrosine to phenylalanine substitution in the cytoplasmic domain of the chimeric receptor and expressed these mutant chimeras in an EPO-responsive erythroleukemia cell line, ELM-I-1. Mutant chimeric receptors retaining either Tyr343 or Tyr401 could activate STAT5, judged by tyrosine-phosphorylation of STAT5 and induction of CIS, a target gene of STAT5. These mutants were able to induce erythroid differentiation. However, a chimeric receptor containing both Y343F and Y401F mutations could not activate STAT5 nor induce erythroid differentiation. Thus, Tyr343 or Tyr401 of the EPO receptor are independently necessary for erythroid differentiation as well as STAT5 activation. Moreover, exogenous expression of dominant-negative STAT5 suppressed EPO-dependent erythroid differentiation. These findings suggest that STAT5.

AB - Interaction between erythropoietin (EPO) and its membrane receptor induces the proliferation and differentiation of erythroid progenitors. EPO has been shown to activate the JAK2-STAT5 pathway in various hematopoietic cell lines, although the physiological role of this pathway is unclear. We have previously shown that epidermal growth factor activates a chimeric receptor bearing the extracellular domain of the epidermal growth factor receptor linked to the cytoplasmic domain of the EPO receptor, resulting in proliferation of interleukin-3-dependent hematopoietic cells and erythroid differentiation (globin synthesis) of EPO-responsive erythroleukemia cells. In the present study, we introduced various deletion and tyrosine to phenylalanine substitution in the cytoplasmic domain of the chimeric receptor and expressed these mutant chimeras in an EPO-responsive erythroleukemia cell line, ELM-I-1. Mutant chimeric receptors retaining either Tyr343 or Tyr401 could activate STAT5, judged by tyrosine-phosphorylation of STAT5 and induction of CIS, a target gene of STAT5. These mutants were able to induce erythroid differentiation. However, a chimeric receptor containing both Y343F and Y401F mutations could not activate STAT5 nor induce erythroid differentiation. Thus, Tyr343 or Tyr401 of the EPO receptor are independently necessary for erythroid differentiation as well as STAT5 activation. Moreover, exogenous expression of dominant-negative STAT5 suppressed EPO-dependent erythroid differentiation. These findings suggest that STAT5.

UR - http://www.scopus.com/inward/record.url?scp=0030929322&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030929322&partnerID=8YFLogxK

U2 - 10.1074/jbc.272.13.8149

DO - 10.1074/jbc.272.13.8149

M3 - Article

C2 - 9079629

AN - SCOPUS:0030929322

VL - 272

SP - 8149

EP - 8152

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 13

ER -